liposomal doxorubicin
liposomal doxorubicin is a pharmaceutical drug with 55 clinical trials. Currently 10 active trials ongoing. Historical success rate of 63.6%.
Success Metrics
Based on 21 completed trials
Phase Distribution
Phase Distribution
14
Early Stage
28
Mid Stage
10
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
58.3%
21 of 36 finished
41.7%
15 ended early
10
trials recruiting
55
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma
Clinical Trials (55)
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma
ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma
Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
A Study of Liposomal Doxorubicin+Docetaxel+Trastuzumab+Metformin in Operable and Locally Advanced HER2 Positive Breast Cancer
Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer
MITO-2: A Study Comparing 2 Chemotherapy Regimens (Carboplatin/Liposomal Doxorubicin vs Carboplatin/Paclitaxel) in Patients With Ovarian Cancer
Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma
AZD2281 in Combination With Liposomal Doxorubicin in Advanced Solid Tumours
AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer
Camrelizumab in Combination With PLD and Losartan in Patients With TNBC Who Have Received ≦ 1 Line of Chemotherapy
A Registry Study in Lymphoma Patients Treated With Liposomal Doxorubicin
Association of Survival With Maintenance Therapy in Patients With Metastatic Breast Cancer After First-line Chemotherapy
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 55